Table 2 . Combination of immunotherapy and chemotherapy
ANTI-PD-1
PHASE 0 |
NCT02630823 |
Pembrolizumab / |
|
|
MK-3475 ( anti-PD-1 ) |
PHASE I |
NCT02309177 |
Nivolumab / Opdivo |
|
|
( anti-PD-1 ) |
IMMUNOTHERAPY CHEMOTHERAPY REGIMEN CONDITION OTHER THERAPIES
NCT02622074 Pembrolizumab / MK-3475 / Keytruda
1 . Paclitaxel and carboplatin Endometrial cancer Radiation
1 . Nab-paclitaxel 2 . Nab-paclitaxel and carboplatin 3 . Nab-paclitaxel and gemcitabine
1 . Nab-paclitaxel , anthracycline , and cyclophosphamide 2 . Nab-paclitaxel , anthracycline , cyclophosphamide , and carboplatin
ER +/ HER2- breast cancer , pancreatic cancer , NSCLC
NCT01840579 |
1 . Cisplatin and pemetrexed |
Stage IIIB-IV NSCLC |
|
|
2 . Carboplatin and paclitaxel |
|
|
NCT02621398 |
1 . Paclitaxel and carboplatin |
NSCLC |
Radiation |
NCT02546531 1 . Gemcitabine Advanced pancreatic cancer Defactinib ( FAK inhibitor )
NCT01822652 1 . Cyclophosphamide and fludarabine Persistent or relapsed neuroblastoma T-cell lymphocyte infusion
TNBC
NCT02437370
1 . Docetaxel 2 . Gemcitabine
Platinum pre-treated urothelial cancer
PHASE I / II NCT02331251 Pembrolizumab / MK-3475 / Keytruda
1 . Gemcitabine 2 . Gemcitabine and docetaxel 3 . Gemcitabine and vinorelbin 4 . Liposomal doxorubicin
Breast cancer , sarcoma , pancreatic cancer , SCLC , ovarian cancer
NCT02513472 |
1 . Eribulin mesylate |
TNBC previously treated with 0-2 |
|
|
chemotherapy regimens |
NCT02422381 |
1 . Gemcitabine |
NSCLC , previously treated |
NCT02382406 1 . Carboplatin and nab-paclitaxel NSCLC NCT02039674
1 . Carboplatin and paclitaxel 2 . Carboplatin and paclitaxel + bevacizumab 3 . Carboplatin and pemetrexed
Metastatic or unresectable NSCLC ipilimumab , gefitinib ( EGFR tyrosine kinase inhibitor ), or erlotinib ( protein kinase inhibitor )
NCT02451982 |
Nivolumab / Opdivo |
1 . Cyclophosphamide |
Advanced or metastatic melanoma |
GVAX ( pancreatic cancer |
|
|
|
|
vaccine ) |
PHASE II |
NCT02591615 |
Pembrolizumab / |
|
|
MK-3475 / Keytruda |
1 . Carboplatin , paclitaxel , and pemetrexed
NCT02551432 1 . Paclitaxel Refractory SCLC
Chemotherapy-naïve stage IV NSCLC
NCT02549209 1 . Paclitaxel and carboplatin Advanced or recurrent endometrial cancer NCT02608684 1 . Gemcitabine and cisplatin Platinum-resistant ovarian cancer NCT02335411
1 . Cisplatin and 5-fluorouracil ( or capecitabine – Japan only )
Treatment-naïve gastric or gastroesophageal adenocarcinoma
NCT01313416 CT-011 ( anti-PD-1 ) 1 . Gemcitabine Resected pancreatic cancer
NCT02605967 |
PDR001 ( anti-PD-1 ) |
1 . Investigator ’ s choice |
Advanced nasopharyngeal carcinoma resistant |
|
|
|
to platinum-based chemotherapy |
PHASE III |
NCT02358031 |
Pembrolizumab / |
|
|
MK-3475 / Keytruda |
1 . Cisplatin , carboplatin , and 5-fluorouracil Recurrent or metastatic squamous cell cancer of the head and neck
NCT02494583 1 . Cisplatin and 5-fluorouracil PD-L1-positive gastric adenocarconima
NCT02578680 |
1 . Cisplatin , carboplatin , and pemetrexed |
NSCLC |
Folic acid , vitamin B12 , and |
|
|
|
dexamethasone |
ANTI-PD-L1 |
|
|
|
PHASE I NCT02508870 Atezolizumab /
MPDL3280A PHASE I / II NCT02628132 Durvalumab /
MEDI4736 PHASE II NCT02685059 Durvalumab /
MEDI4736 NCT02525757 Atezolizumab /
|
|
MPDL3280A |
PHASE III |
NCT02425891 |
Atezolizumab / |
1 . Azacitidine Myelodysplastic syndromes
1 . Paclitaxel TNBC
1 . Nab-paclitaxel , epirubicin , and TNBC
cyclophosphamide |
|
|
1 . Carboplatin and paclitaxel |
Lung cancer , including NSCLC |
Radiation |
1 . Nab-paclitaxel Metastatic breast cancer , previously untreated
MPDL3280A
NCT02367781 1 . Carboplatin and nab-paclitaxel Chemotherapy-naïve NSCLC
NCT02366143 1 . Carboplatin and paclitaxel Chemotherapy-naïve NSCLC Bevacizumab
NCT02367794
NCT02657434
1 . Carboplatin and nab-paclitaxel
2 . Carboplatin and paclitaxel 1 . Carboplatin and pemetrexed
2 . Cisplatin and pemetrexed
Squamous NSCLC
Metastatic non-squamous NSCLC
( anti-VEGF )
7